Latest Telehealth News

Page 1 of 9
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.
Ada Torres
Ada Torres
30 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.
Ada Torres
Ada Torres
16 Oct 2026
Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.
Ada Torres
Ada Torres
13 Oct 2026
BCAL Diagnostics has begun introducing ClearNote Health’s Avantect Multi-Cancer blood test in Australia, starting with Sydney and Melbourne. The test reported 56.2% sensitivity and 98.4% specificity in a case-control validation study, but the company says a negative result does not rule out cancer.
Ada Torres
Ada Torres
23 Sept 2026
EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.
Ada Torres
Ada Torres
3 Sept 2026
LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.
Ada Torres
Ada Torres
28 Aug 2026
Doctor Care Anywhere delivered a 27% rise in EBITDA and doubled free cash flow in H1 2026, driven by operational efficiencies and a strategic entry into the UK weight management market via acquisition.
Ada Torres
Ada Torres
17 Aug 2026
LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.
Ada Torres
Ada Torres
11 Aug 2026
BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.
Ada Torres
Ada Torres
30 July 2026

Browse the archive

Full archive